CV301 Phase 1/2 Combination Clinical Study
Marking Bavarian Nordic’s first entry into lung cancer clinical trials with novel immunotherapy candidate CV301.
MAGNI-Lung-01 is a phase 1/2 trial of CV301 in combination with OPDIVO® (nivolumab), versus nivolumab in subjects with previously treated non-small cell lung cancer (NSCLC).
The rationale for combining CV301 with a PD-1 inhibitor is based on the hypothesis that CV301 can induce a specific immune response in the tumor, and that in combination with an anti-PD-1 inhibitor, may augment the T cell -mediated immune response generated by CV301 by blocking the inhibitory signal of the PD-1.
MAGNI-Lung-01 is a randomized, open-label, phase 1/2 study to investigate the safety and tolerability of CV301 in combination with nivolumab, compared to nivolumab alone in subjects with previously treated NSCLC.
The study was initiated in 4Q 2016. The final data collection date for the primary outcome measure is December 2020.
Additional details can be found here: